# EdiPro Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edipro-pharmaceutical

- Headquarters: Chengdu, China
- Latest round: Angel (May 24, 2022)
- Investors on record: 1

## About

Based in Sichuan, China and founded in 2022, Chengdu Qianhua Hesheng Pharmaceutical Technology Co., Ltd., dba EdiPro Pharmaceutical, is dedicated to building an innovative drug platform that develops novel therapeutics for major diseases and rare genetic disorders. The company was founded by Dr. Shixian Lin, a professor and doctoral supervisor at the Institute of Life Sciences, Zhejiang University.

In September 2026, EdiPro Pharmaceutical closed a round of Pre-series A funding led by Tao Capital with participation from Chengdu Science and Technology Venture Capital Group.

EdiPro Pharmaceutical focuses on the development of long-acting peptides, cyclic peptides and antibody-peptide conjugates. leveraging a synthetic biology platform powered by its self-developed chimeric translation system, targeting major chronic metabolic diseases, as well as genetic diseases caused by nonsense mutations. 

The company generates revenue from developing novel peptide and protein-based drugs.

The company will primarily use the Pre-series A funding to refine the proprietary technology platform and to conduct preclinical studies on existing candidate molecules.

## Funding rounds

- Angel, May 24, 2022 — Casstar Capital

## Investors

- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel